Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

OBJECTIVE: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis. METHODS: After 2 years of do...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Stephen L., Kappos, Ludwig, Arnold, Douglas L., Bar-Or, Amit, Brochet, Bruno, Naismith, Robert T., Traboulsee, Anthony, Wolinsky, Jerry S., Belachew, Shibeshih, Koendgen, Harold, Levesque, Victoria, Manfrini, Marianna, Model, Fabian, Hubeaux, Stanislas, Mehta, Lahar, Montalban, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682822/
https://www.ncbi.nlm.nih.gov/pubmed/32690791
http://dx.doi.org/10.1212/WNL.0000000000010376

Ejemplares similares

Ejemplares similares